1.2100 0.00 (0.00%)
After hours: 6:39PM EDT
|Bid||1.2000 x 29200|
|Ask||1.2000 x 39400|
|Day's Range||1.0800 - 1.2500|
|52 Week Range||0.9500 - 6.9900|
|Beta (3Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.83|
Investing in stocks comes with the risk that the share price will fall. And there's no doubt that Geron Corporation...
Geron Corporation (GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations to support the planned opening of the Phase 3 portion of IMerge in lower risk myelodysplastic syndromes for screening and enrollment in the summer of 2019. As Vice President, Human Resources, Ms. Odam will lead all aspects of a comprehensive human resources function, including oversight of policies and operations for leadership and talent management, training, organizational development, operational effectiveness and workforce planning.
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased.
Geron Corporation (GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Congress of the European Hematology Association (EHA). The KOLs will reprise the presentations made at EHA, and Geron’s management team will provide an update regarding progress towards the Company’s 2019 objectives, including the opening of the planned Phase 3 portion of IMerge for screening and enrollment in the summer of 2019. Uwe Platzbecker, M.D., Director, Medical Department I – Hematology and Cell Therapy, University of Leipzig Medical Center, Leipzig, Germany, will review efficacy and safety data presented at EHA from the Phase 2 portion of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes.
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Geron Corporation (GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th European Hematology Association (EHA) Annual Congress to be held in Amsterdam, the Netherlands, from June 13-16, 2019. “We appreciate the opportunity to present additional data and analyses at EHA from the ongoing imetelstat clinical trials,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
Geron Corporation (GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward with the planned opening of the Phase 3 clinical trial in lower risk myelodysplastic syndromes for screening and enrollment, which we continue to expect by mid-year 2019,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “Our new development team has refined our regulatory strategies for myelofibrosis, which we plan to discuss at an End of Phase 2 meeting with the FDA by the end of the first quarter of 2020.
Geron Corporation (GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing.
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
The Menlo Park, California-based company said it had a loss of 5 cents per share. The drugmaker posted revenue of $57,000 in the period. The company's shares closed at $1.82. A year ago, they were trading ...
MENLO PARK, Calif., May 02, 2019 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019. As of the quarter-end, the.
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of Geron Corporation (NASDAQ:GERN) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies...
MENLO PARK, Calif., April 18, 2019 -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three.
Geron Corporation (NASDAQ: GERN ) announced in September that Johnson & Johnson (NYSE: JNJ )'s Janssen unit opted to terminate a collaboration and licensing agreement between the companies for imetelstat, ...
April 8 (Reuters) - Geron Co Ltd: * SAYS CONTROLLING SHAREHOLDER PLANS TO UNLOAD UP TO 6 PERCENT STAKE IN THE COMPANY WITHIN SIX MONTHS Source text in Chinese: https://bit.ly/2IiMtRX Further company coverage: ...
MENLO PARK, Calif., April 02, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.
MENLO PARK, Calif., March 28, 2019 -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its.